undenatured type II collagen · UC-II collagen · chicken collagen · type II collagen
40 mg · gluten-free · 60 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
UC-II is a patented form of undenatured (native) type II collagen derived from chicken sternum cartilage. Unlike hydrolyzed collagen, which is broken down into peptides, UC-II maintains its native triple-helix structure, which is essential for its mechanism of action through oral tolerance.
UC-II works through a mechanism called oral tolerance. When small amounts of undenatured type II collagen reach the gut-associated lymphoid tissue (GALT), they trigger regulatory T-cells that downregulate the immune response against the body's own cartilage. This reduces autoimmune-mediated cartilage degradation.
Adults with osteoarthritis, individuals with exercise-induced joint discomfort, those seeking alternatives to glucosamine and chondroitin, athletes with joint stress.
People with chicken allergies (source material), those with autoimmune conditions (theoretical concern), pregnant or breastfeeding women (insufficient safety data), children, vegetarians and vegans (animal-derived).
Pick a depth — minimum to maximal coverage
No full stack configured.
Click individual supplement pills above to buy each on Amazon India.
✓ Morning on empty stomach, 30 minutes before breakfast
✓ Critical: take on empty stomach. Protein meals interfere with oral tolerance mechanism.
UC-II works through a mechanism called oral tolerance.
Each bar = one cited trial. Effect varies by methodology, dose, and population.
Elevated inflammation cohort (n≈70)
Target hsCRP <1.0 mg/L for low cardiovascular risk.
see study
→ UC-II 40 mg/day improved WOMAC score by 33% and VAS pain by 40% vs 14% and 15% for glucosamine + chondroitin (N=52, 90 days)
see study
→ UC-II 40 mg/day reduced knee extension discomfort by 20% vs placebo in healthy adults (N=55, 120 days)
see study
→ UC-II 40 mg/day significantly improved WOMAC, VAS, and Lequesne index vs placebo (N=191, 180 days)
B · Unique oral tolerance mechanism; outperformed glucosamine+chondroitin in head-to-head trial; consistent efficacy across multiple RCTs; small dose (40 mg) is clinically effective; requires empty stomach administration
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: See richResearch section. Clinical evidence for joint and bone support from multiple RCTs.
How to use UC-II specifically for joint pain — the right dose, timing, blood markers to track, and how to know if it is working.
A clinical evidence review of UC-II — RCT data, effect sizes, evidence grade, and what the numbers mean for your specific situation.
Everything you need to know about UC-II — mechanism, dose, safety, buying guide for India, and what the research actually says.
SacredBod's longer take on UC-II — context the structured blocks above don't capture.
UC-II represents a fundamentally different approach to joint health. While glucosamine and chondroitin provide structural building blocks, and MSM supplies sulfur for collagen synthesis, UC-II works through immunological modulation. The undenatured (native) type II collagen maintains its triple-helix structure, which is recognized by the gut-associated lymphoid tissue as a familiar protein. This triggers regulatory T-cells that suppress the autoimmune response against joint cartilage—a mechanism called oral tolerance that has been validated in both animal models and human trials.
The head-to-head trial is particularly compelling. Crowley and colleagues (2009, International Journal of Medical Sciences, PMID 19721771) randomized 52 patients with knee osteoarthritis to UC-II 40 mg daily, glucosamine 1,500 mg + chondroitin 1,200 mg daily, or placebo for 90 days. The results favored UC-II dramatically: WOMAC score improved by 33% with UC-II versus 14% with glucosamine/chondroitin. Visual analog pain scores improved by 40% with UC-II versus 15% with the combination. This is not merely a positive result; it is a direct superiority demonstration against the most widely used joint supplement combination. The effect size was large enough to be clinically meaningful for daily functioning.
The mechanism requires precise administration. UC-II must be taken on an empty stomach because protein-rich meals interfere with the oral tolerance mechanism. The 40 mg dose is surprisingly small compared to gram-dose supplements, but it is sufficient to trigger the immunological response without overwhelming the system. Lugo and colleagues (2016, Nutrition Journal, PMID 26761854) extended the evidence to healthy adults, showing that UC-II reduced knee extension discomfort during exercise by 20% compared to placebo over 120 days. This suggests the benefit is not limited to established osteoarthritis but may also support joint resilience in active individuals.
The larger trial confirmed efficacy. Bagchi and colleagues (2017, International Journal of Medical Sciences, PMID 28951549) randomized 191 knee osteoarthritis patients to UC-II 40 mg or placebo for 180 days. UC-II significantly improved all outcome measures—WOMAC, VAS pain, and Lequesne index—compared to placebo. The consistency across three independent trials, using different populations and durations, strengthens confidence. The honest framing: UC-II has a unique mechanism, consistent clinical efficacy at a tiny dose, and a good safety profile. The requirement for empty-stomach administration is critical and often ignored by consumers, potentially explaining some variability in response.
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
